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Purpose/Objective: SBRT treatment processes are complex 
and at risk of incidents/accidents due of the use a high 
dose/high precision treatment session. Our objective was to 
identify prospectively the risk of incident/accident at the 
time of deployment of SBRT within our radiotherapy 
department. 
Materials and Methods: Risk Analysis (RA) of SBRT was 
performed using the Failure Mode and Effects Analysis (FMEA) 
methodology and an existing chart review on 'consultation' 
and 'RT precription' for IMRT/IGRT which was updated by a 
multidisciplinary team (Physician, Physicist, Quality manager, 
Dosimetrist, RTTechnician). The risk level of various steps 
within the risk matrix was re-stated, using the classical 
scoring system taking into account the product of Probability, 
Severity and Detection. Corrective actions were then 
proposed when the risk level was deemed inacceptable. 
Results: Only a few risk levels were found higher due to the 
implementation of SBRT within the 'consultation' and 'RT 
prescription' flow-chart (mainly for steps concerning side 
effects and premedication supposed to prevent them) but 
their scores remained tolerable and were discussed within 
our multidisciplinary team. Of notice was the risk level of 
one step concerning the input of SBRT prescription (dose, 
fractionation, timing) in the dosimetry system though: the 
corresponding score rose significantly, as compared to 
IMRT/IGRT, reaching 45 and was deemed inacceptable ( 36 or 
more), requiring an immediate corrective action. The side of 
the volume to-be treated was also critical (score of 30) and 
was to be adressed by the same corrective action. The 
possible causes for those failure modes were essentially 
human errors. Our multidisciplinary team made the decision 
to implement a 'never-event' check list allowing a cross-
control of the treatment parameters by a dosimetrist and a 
physician altogether before the validation of dosimetry. A 
new round of grading will then be performed within 3 months 
in order to evaluate the impact of our corrective actions on 
risk-levels. Results will be shown at the meeting. 
Conclusions: Inacceptable risk levels through the treatment 
process were identified using RA based on the FMEA 
methodology. Where and when human errors could yield to a 
radiotherapy accident, a proper 'never-event' check-list was 
designed to deter the risk to the patient. The impact of this 
corrective action on risk-levels will be shown at the meeting. 
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Purpose/Objective: The purpose of this study is to quantify 
and compare different dose-volume constraints for the organs 
at risk (OARs) in breast cancer radiotherapy treatment for 
whole breast irradiation (WBI) without boost, and breast with 
simultaneous integrated boost (SIB). 
Materials and Methods: 54 breast cancer patients were 
evaluated. Studies were grouped regarding the type of 
treatment. The fractionation scheme was 2.0 Gy per fraction 
for WBI only and 2.4 Gy per fraction for SIB. Treatment 
planning was carried out using XiO TPS. Two tangential 
beams with field in field technique were used. 
The following parameters were recorded and evaluated for 
both treatment schemes:  
-Both lungs (considered as a single OAR): Dmean (mean 
dose), V5Gy, and V20Gy 
-Ipsilateral lung: Dmean, V5Gy, V20Gy 
-Heart: Dmean, V25Gy 
-Contralateral breast: Dmax, V10Gy 
-Gantry angles were also recorded as a possible independent 
influence variable. 
 
Results: 
 
Dmean for the heart is practically the same for both 
treatments. For the ipsilateral lung, Dmean, V5Gy and V20Gy 
are slightly higher in the case of SIB treatment. The same 
occurs for both lungs. 
The significance of these differences has been tested, with a 
5% significance level. The results and the p-value are shown 
in the Table 1. The differences are statistically significant for 
the lungs. 
In the contralateral breast the only differences are in the 
maximum dose. In both treatments, for the right cases this 
dose is higher than for the left cases. The gantry angles for 
the right cases are, in average: 55,61o for the medial-lateral 
beam (ML) and 126,58o for the lateral-medial beam (LM). In 
the left cases: 51,09o for the ML and 132,70o for the LM 
(gantry angles have been made simmetrical in order to 
compare left and right cases). 
Conclusions: The results shown before have demonstrated 
that in the SIB treatment, the lung receives a higher mean 
dose, and larger V5Gy and V20Gy. Moreover, we can conclude 
that these differences between WIB and SIB are statistically 
significant. The differences are not statistically significant in 
the case of the heart. 
For the right side cases, in both type of treatments the 
contralateral breast receives more maximum dose. This could 
be because of the different beam arrangement used for these 
cases. In left breast cases, the beam arrangement has a 
strong dependency with the heart position. The p-value 
shows that the differences between the beam arrangement 
